Bankrupt DNA testing company 23andMe to be acquired by Regeneron for $256 million |

Regeneron Pharmaceuticals has introduced it can purchase 23andMe, the as soon as high-flying shopper DNA testing company, for $256 million via a chapter public sale. The deal comes after 23andMe filed for Chapter 11 chapter safety in March amid plummeting demand for its ancestry kits and fallout from a 2023 knowledge breach. Regeneron, a serious participant in biotech and prescription drugs, mentioned it can honor 23andMe’s privateness commitments and cling to authorized safeguards round buyer genetic knowledge. The acquisition raises questions on how the huge trove of private well being info from 15 million customers will now be dealt with.

Why 23andMe went bankrupt

Once a pioneer within the shopper DNA testing market, 23andMe confronted a gentle decline in demand as public curiosity in ancestry testing waned. The state of affairs worsened after a 2023 knowledge breach compromised the genetic knowledge of hundreds of thousands of consumers, damaging the company’s credibility and triggering lawsuits. At the identical time, the agency struggled to pivot to new enterprise fashions, together with well being insights and telemedicine, which failed to generate enough income. Mounting losses and restricted investor confidence finally pushed the company to search chapter safety.

Privacy considerations draw scrutiny

Regeneron mentioned it can adjust to 23andMe’s privateness insurance policies and related legal guidelines when dealing with buyer knowledge. A court-appointed overseer will monitor the company’s knowledge use, a safeguard agreed upon in April amid fears that delicate genetic profiles might fall into the incorrect fingers. Lawmakers and privateness advocates had raised alarms when 23andMe first entered chapter, warning that shopper knowledge should be protected even in the midst of a sale.

Data breach and enterprise decline

The sale marks a major flip for 23andMe, which was as soon as among the many main private genomics firms. However, demand for at-home DNA testing declined sharply lately, and the company’s fame took successful after a serious 2023 knowledge breach uncovered the private knowledge of hundreds of thousands. The incident led to lawsuits and additional eroded public belief, contributing to its monetary troubles.

Exclusion of Lemonaid Health

As a part of the acquisition deal, Regeneron will take management of all 23andMe items besides for Lemonaid Health, its telehealth subsidiary. 23andMe plans to shut down Lemonaid Health as a part of its restructuring. The core genetic testing enterprise, nevertheless, will proceed working as an entirely owned unit underneath Regeneron.

What occurs subsequent

The firms anticipate to shut the transaction by the third quarter of 2025. Once accomplished, 23andMe will operate as both a direct or oblique subsidiary of Regeneron. While Regeneron’s particular plans for the information and know-how usually are not but clear, the company says it’s dedicated to transparency and authorized compliance, particularly because it navigates public and regulatory scrutiny over the way forward for shopper genetic info.